Oxygen Biotherapeutics, Inc. is a development stage company developing biotechnology products that deliver oxygen to target tissues in the body. The company develops Oxycyte, an oxygen carrier for use in situations of acute ischemia, which is in clinical trial for the treatment of traumatic brain injury. The company also offers the Dermacyte line of topical cosmetic products, which promote the appearance of skin health, and Wundecyte, a wound-healing gel. For more information, visit the company’s website at www.oxybiomed.com.